Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 5/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 2/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035513 | 0.82 | WEE1 (0.43) | WEE1PAK4PKN1MAP4K1JAK2 | |
| SCHEMBL15035476 | 0.82 | WEE1 (0.45) | WEE1PAK4PKN1MAP4K1JAK2 | |
| SCHEMBL15035584 | 0.81 | WEE1 (0.46) | WEE1PAK4PKN1MAP4K1JAK2 | |
| SCHEMBL15035412 | 0.79 | WEE1 (0.44) | WEE1PAK4PKN1MAP4K1JAK2 | |
| SCHEMBL15035395 | 0.78 | CDK4 (0.37) | WEE1PAK4PKN1JAK2BRD4 | |
| SCHEMBL15035401 | 0.78 | PAK4 (0.38) | WEE1PAK4PKN1JAK2BRD4 | |
| SCHEMBL15035303 | 0.77 | WEE1 (0.44) | WEE1PAK4PKN1MAP4K1JAK2 | |
| SCHEMBL15035514 | 0.75 | CDK4 (0.54) | — | |
| SCHEMBL15041313 | 0.74 | CDK4 (0.49) | WEE1PAK4PKN1BRD4 | |
| SCHEMBL15035543 | 0.74 | CDK4 (0.49) | WEE1PAK4PKN1JAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | WEE1 545/4885PAK4 5/4885PKN1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.